Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IWOT trial in resected IDH-mutant 1p/19q-intact lower-grade astrocytoma
NL-OMON48284Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in astrocytoma and glioma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Next intervention free survival. Started Jul 2021; status: active, not recruiting.
02
Drugs
temozolomide
03
Conditions
astrocytomaglioma
Beyond the preview
Go deeper on NL-OMON48284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48284.